October 22, 2009 By:Marissa Shapiro
Why knowing a drug's risk and preparing for a risk evaluation mitigation strategy early on will considerably benefit a drug's development.
 |
October 1, 2009 By:Lisa Henderson
What constitutes a conflict of interest for the clinical investigator is what PhRMA is addressing with voluntary guidelines.
 |
October 1, 2009 By:Juliane Carvalho, Ekopimo Ibia
The region and its regulatory agencies try to keep up with the rapidly growing clinical trials market.
 |
September 30, 2009
A recent, free report, reveals biotech professionals' evaluations of potential business model alternatives for the future.
 |
September 11, 2009 By:David Levin
How changing times require a new approach to partnerships.
 |
September 1, 2009 By:Nermeen Varawalla
The once recession-proof industry must now seek out opportunities to defend itself from potential downfalls.
 |
|